Zolmiptriptan Tablet, Orally Disintegrating
Product Images NDC 68462-500

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zolmiptriptan (NDC 68462-500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton2.5mg6s.jpg.jpg

Packaging label for Zolmitriptan Orally Disintegrating Tablets, USP, 2.5 mg strength. The label indicates a package of 6 orally disintegrating tablets, Rx only, manufactured by Glenmark Pharmaceuticals Ltd. and labeled for Glenmark Pharmaceuticals Inc., USA. The label includes storage instructions, warnings, barcode, and manufacturer contact details.*

FDA Label Image

Carton5 mg3s

Label for zolmitriptan orally disintegrating tablets, USP, 5 mg strength. The label indicates the tablets are prescription-only and packaged as 3 orally disintegrating tablets. It features the Glenmark logo and includes manufacturing details from Glenmark Pharmaceuticals Ltd., India, and Glenmark Pharmaceuticals Inc., USA.*

FDA Label Image

Figure1

A line graph showing the estimated probability of response over time from the initial dose for zolmitriptan in 1 mg, 2.5 mg, and 5 mg doses compared to a placebo. The x-axis indicates time in hours (0 to 4), and the y-axis shows the estimated probability of response, ranging from 0% to 100%. The graph illustrates increasing response probabilities for all zolmitriptan doses over time, with higher doses generally showing higher response rates than placebo.*

FDA Label Image

Figure2

A line graph depicting estimated probability of remediation of rescue over 24 hours from the initial dose. The graph compares four groups: placebo, 1 mg, 2.5 mg, and 5 mg doses, showing probability percentages on the vertical axis and time in hours on the horizontal axis.*

FDA Label Image

Figure3

A line graph showing estimated probability of response over time from initial dose for zolmitriptan orally disintegrating tablets 2.5 mg compared to placebo. The x-axis represents time in hours (0 to 2 hours), and the y-axis represents probability of response from 0% to 100%. The zolmitriptan line shows increasing response probability over time, higher than placebo throughout the 2-hour period.*

FDA Label Image

Figure4

A line graph comparing the estimated probability of medication or rescue between zolmitriptan orally disintegrating tablets 2.5 mg and placebo over 24 hours from the initial dose. The graph shows zolmitriptan reaching a higher probability more rapidly than placebo.*

FDA Label Image

Logo

FDA Label Image

Structure

Chemical structure of zolmitriptan, the active ingredient in zolmiptriptan orally disintegrating tablets by Glenmark Pharmaceuticals Inc. The structure shows a bicyclic compound with a lactam ring and an indole moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.